1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Bristol’s Growth Plans Take A Hit As Cobenfy Fails As A Schizophrenia Add-On

Setback Follows Camzyos Stumble In nHCM

 
• By Mandy Jackson

Cobenfy is approved as a monotherapy, but failed in the adjunctive setting when combined with generic atypical antipsychotics, giving BMS a second Phase III failure in two weeks.

Prescribers already treat schizophrenia with combination therapy without approved adjunctive medicines (Shutterstock)
Key Takeaways
  • Bristol’s Cobenfy did not achieve statistical significance on the primary endpoint in the Phase III ARISE clinical trial testing the drug as an add-on to antipsychotic medicines in schizophrenia.
  • Approved in the US as a monotherapy in September 2024, doctors already prescribe Cobenfy in the adjunctive setting for some patients, given the need for additive medicines and long-term practice of combination therapy despite no drug approvals for adjunctive use in schizophrenia.
  • Analysts expect some impact on sales, but most say adjunctive use is likely to continue. Even so, investor confidence in BMS took a hit after the company’s other recent setback for Camzyos.

Bristol Myers Squibb made a $14bn gamble when it agreed to buy Karuna Therapeutics in late 2023 for its drug that was pending US Food and Drug Administration approval at...

BMS announced after the stock market closed on 22 April that its oral M1/M4 muscarinic receptor agonist/muscarinic receptor antagonist did not achieve statistical significance as an add-on therapy on the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

 
• By Jessica Merrill

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.

ASCO: Zepzelca Tecentriq Combo A Lung Cancer Success For Jazz and Roche

 
• By Andrew McConaghie

Small-cell lung cancer treatment is rapidly evolving, but Jazz and Roche are set to create a new maintenance therapy setting with their Zepzelca plus Tecentriq combination.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By Andy Smith

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.

More from Scrip

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By Andy Smith

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.

ASCO: J&J Banks On T-Cell Engager’s Safety In Prostate Cancer

 
• By Andrew McConaghie

The company highlighted the KLK2-targeting agent’s safety at ASCO but it may have to rely on combinations to make pasritamig competitive.

ASCO: Regeneron Looks To Become Bigger Immuno-Oncology Player

 
• By Alaric DeArment

The drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.